Mechanisms for 5-Fluorouracil Resistance in Human Colon Cancer DLD-1 Cells
スポンサーリンク
概要
- 論文の詳細を見る
A 5-fluorouracil (5-FU)-resistant subline, DLD-1/5-FU, was established by repeated 5-d exposures of human colon cancer DLD-1 cells to 5-FU. DLD-1/5-FU cells were 41- and more than 75-fold resistant to 96-h and 1-h exposures to 5-FU, respectively. When exposed to 5-FU, DLD-1/5-FU cells exhibited marked resistance to in situ thymidylate synthase (TS) inhibition by 5-FU as compared to DLD-1 cells, and incorporation of 5-FU into cellular RNA in DLD-1/5-FU cells decreased to 25% of that in DLD-1 cells. As causes of resistance to DNA and RNA-directed actions of 5-FU, remarkable reduction of intracellular levels of both 5-fluorouridine 5'-triphosphate (FUTP) and 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP) in DLD-1/5-FU cells was confirmed. It was found that activities of uridine kinase, orotate phosphoribosyltransferase and thymidine kinase of DLD-1/5-FU cells were significantly lower than those of the parent cells. Intracellular levels of TS were similar between the two cell lines. These results indicated that the mechanism of resistance to 5-FU in DLD-1/5-FU cells involves reduced enzymatic activation of 5-FU.
- 公益社団法人日本薬学会の論文
- 1998-06-15
著者
-
INABA Makoto
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
-
MITSUHASHI Junko
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
-
Inaba M
Cancer Chemotherapy Center Japanese Foundation For Cancer Research
-
Inaba Makoto
Cancer Chemotherapy Center Japanese Foundation For Cancer Research
-
Inaba M
Tokai Univ.
-
Naoe Yoshinori
Department Of Pharmacology Pharmacological Research Laboratories Fujisawa Pharmaceutical Co. Ltd.
-
Naoe Yoshinori
(present Address)product Development Laboratories Fujisawa Pharmaceutical Co. Ltd.
-
Mitsuhashi J
Cancer Chemotherapy Center Japanese Foundation For Cancer Research
-
Mitsuhashi Junko
Cancer Chemotherapy Center Japanese Foundation For Cancer Research
関連論文
- CP8-8 FK228, histone deacetylase inhibitor : A novel drug for the treatment of prostate and renal cancers
- Intracellular Glutathione Levels in Human Colon Cancer Cells Naturally Resistant to Cross-Linking Agents
- COMPARATIVE ANALYSIS OF HEPATIC UPTAKE AND BILIARY EXCRETION OF VINCRISTINE AND VINBLASTINE IN PERFUSED RAT LIVER
- Reduced Activity of Anabolizing Enzymes in 5-Fluorouracil-resistant Human Stomach Cancer Cells
- Anti-cachectic Effect of FK317, a Novel Anti-cancer Agent, in Colon26 and LX-1 Models in Mice
- FK317, a Novel Substituted Dihydrobenzoxazine, Exhibits Potent Antitumor Activity against Human Tumor Xenografts in Nude Mice
- Different Effects of FK317 on Multidrug-resistant Tumor in vivo and in vitro
- Cytotoxic Mechanisms of FK317, a New Class of Bioreductive Agent with Potent Antitumor Activity
- A New Aromatase Inhibitor, FR901537 II.Pharmacological and Antitumor Effects
- Effects of a New Non : Steroidal 5α : Reductase Inhibitor, FK143, on the Prostate Gland in Beagle Dogs
- CONTRIBUTION OF P-GLYCOPROTEIN, ASSOCIATED WITH MULTIDRUG RESISTANCE, TO BILIARY EXCRETION OF VINCRISTINE : A KINETIC ANALYSIS
- Mechanisms for 5-Fluorouracil Resistance in Human Colon Cancer DLD-1 Cells
- Numerical Analysis of Scaling Behavior in 4D Quantum Simplicial Gravity
- Mechanism for Resistance to 5-Fluorouracil in P388 Leukemia Cells
- Increased Sensitivity to Long-term 5-Fluorouracil Exposure of Human Colon Cancer HT-29 Cells Resistant to Short-term Exposure
- MECHANISM FOR REGULATION OF MEMBRANE TRANSPORT OF LIPOPHILIC DRUGS IN MULTIDRUG-RESISTANT TUMOR CELLS